Single Versus Double Dose Praziquantel Comparison on Efficacy and Schistosoma mansoni Re-Infection in Preschool-Age Children in Uganda: A Randomized Controlled Trial

PLoS Neglected Tropical Diseases

Volumn 9, Issue 5, 2015, Pages

  Nalugwa, Allen ^a   Nuwaha, Fred ^a   Tukahebwa, Edridah Muheki ^b   Olsen, Annette ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b MINISTRY OF HEALTH   (Uganda)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PRAZIQUANTEL; ANTHELMINTIC AGENT;

ABDOMINAL PAIN; ARTICLE; BLOODY DIARRHEA; CHILD; DRUG DOSE COMPARISON; DRUG EFFICACY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARASITE EXAMINATION; PATHOGEN CLEARANCE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; UGANDA; VOMITING; AGE; ANIMAL; CONTROLLED STUDY; DRUG EFFECTS; INFANT; NEGLECTED DISEASES; PARASITE IDENTIFICATION; RECURRENT DISEASE; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; ANTHELMINTICS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEGLECTED DISEASES; PARASITE EGG COUNT; PRAZIQUANTEL; RECURRENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TREATMENT OUTCOME; UGANDA;

EID: 84930667897     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003796     Document Type: Article

References (72)

1. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, Sachs JD, Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006;3(5):e102. 16435908
2. Molyneux DH, Hotez PJ, Fenwick A, “Rapid-impact interventions”: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2005;2(11):e336. 16212468
3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25. 16790382
4. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JDF, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86(2):125–39.
5. Chitsulo L, Engels D, Montresor A, Savioli L, The global status of schistosomiasis and its control. Acta Trop. 2000;77(1):41–51. 10996119
6. Loewenberg S, Uganda's struggle with schistosomiasis. Lancet. 2014;383(9930):1707–8. 24843875
7. Savioli L, Gabrielli A, Montresor A, Chitsulo L, Engels D, Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54· 19. Parasitology. 2009;136(13):1677–81. doi: 10.1017/S0031182009991181 19765347
8. WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: World Health Organization; 2002. 12592987
9. Bosompem K, Bentum IA, Otchere J, Anyan W, Brown C, Osada Y, et al. Infant schistosomiasis in Ghana: a survey in an irrigation community. Trop Med Int Health. 2004;9(8):917–22. 15303998
10. Nalugwa A, Olsen A, Tukahebwa M, Nuwaha F, Intestinal schistosomiasis among preschool children along the shores of Lake Victoria in Uganda. Acta Trop. 2015;142:115–21. doi: 10.1016/j.actatropica.2014.11.014 25454166
11. Odogwu S, Ramamurthy N, Kabatereine N, Kazibwe F, Tukahebwa E, Webster J, et al. Schistosoma mansoni in infants (aged< 3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parastol. 2006;100(4):315–26. 16762112
12. Stothard JR, Sousa-Figueiredo JC, Navaratnam AM, Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. 2013. doi: 10.1586/14787210.2013.811931 23879611
13. Montresor A, Stoltzfus RJ, Albonico M, Tielsch JM, Rice AL, Chwaya HM, et al. Is the exclusion of children under 24 months from anthelmintic treatment justifiable? Trans R Soc Trop Med Hyg. 2002;96(2):197–9. 12055814
14. Utzinger J, Bergquist R, Shu-Hua X, Singer BH, Tanner M, Sustainable schistosomiasis control—the way forward. Lancet. 2003;362(9399):1932–4. 14667754
15. Keiser J, Ingram K, Utzinger J, Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control. Parasitology. 2011;138(12):1620–32. doi: 10.1017/S0031182011000023 21349223
16. WHO. Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-age children. 2011.
17. Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, et al. Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Neglect Trop D. 2011;5(5).
18. Doenhoff MJ, Cioli D, Utzinger J, Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–67. doi: 10.1097/QCO.0b013e328318978f 18978535
19. Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C, Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Neglect Trop D. 2009;3(1):e357. doi: 10.1371/journal.pntd.0000357 19159015
20. Cioli D, Pica-Mattoccia L, Basso A, Guidi A, Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23–9. doi: 10.1016/j.molbiopara.2014.06.002 24955523
21. Olliaro P, Delgado-Romero P, Keiser J, The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014;69(4):863–70. doi: 10.1093/jac/dkt491 24390933
22. Fenwick A, Webster JP, Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis. 2006;19(6):577–82. 17075334
23. Crompton DWT, Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers: World Health Organization; 2006.
24. Gabrielli A-F, Montresor A, Chitsulo L, Engels D, Savioli L, Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans R Soc Trop Med Hyg. 2011;105(12):683–93. doi: 10.1016/j.trstmh.2011.08.013 22040463
25. Andrews P, Thomas H, Pohlke R, Seubert J, Praziquantel. Medicinal Res Rev. 1983;3(2):147–200. 6408323
26. Cioli D, Pica-Mattoccia L, Praziquantel. Parastol Res. 2003;90(1):S3–S9. 12811543
27. Harnett W, The anthelmintic action of praziquantel. Parasitol Today. 1988;4(5):144–6. 15463071
28. Giboda M, Smith J, Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice. J Trop Med Hyg. 1994;97(2):98–102. 8170010
29. Renganathan E, Cioli D, An international initiative on praziquantel use. Parasitol Today. 1998;14(10):390–1. 17040826
30. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ. 2007;85(2):91–9. 17308729
31. Standley CJ, Adriko M, Alinaitwe M, Kazibwe F, Kabatereine NB, Stothard JR, Intestinal schistosomiasis and soil-transmitted helminthiasis in Ugandan schoolchildren: a rapid mapping assessment. Geospat Health. 2009;4(1):39–53. 19908189
32. Stothard J, Webster B, Weber T, Nyakaana S, Webster J, Kazibwe F, et al. Molecular epidemiology of Schistosoma mansoni in Uganda: DNA barcoding reveals substantial genetic diversity within Lake Albert and Lake Victoria populations. Parasitology. 2009;136(13):1813–24. doi: 10.1017/S003118200999031X 19627628
33. Tukahebwa EM, Magnussen P, Madsen H, Kabatereine NB, Nuwaha F, Wilson S, et al. A very high infection intensity of Schistosoma mansoni in a Ugandan Lake Victoria fishing community is required for association with highly prevalent organ related morbidity. PLoS Neglect Trop D. 2013;7(7):e2268. doi: 10.1371/journal.pntd.0002268 23936559
34. Standley CJ, Wade CM, Stothard JR, A fresh insight into transmission of schistosomiasis: a misleading tale of Biomphalaria in Lake Victoria. PloS one. 2011;6(10):e26563. doi: 10.1371/journal.pone.0026563 22046308
35. Barakat R, Morshedy HE, Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt. Parasitology. 2011;138(04):440–6.
36. Tukahebwa EM, Vennervald BJ, Nuwaha F, Kabatereine NB, Magnussen P, Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg. 2013;107(6):397–404. doi: 10.1093/trstmh/trt024 23596262
37. Kirkwood B, Sterne J, Essential Medical Statistics: Wiley; 2003.
38. De Vlas S, Gryseels B, Underestimation of Schistosoma mansoni prevalences. Parasitol Today. 1992;8(8):274–7. 15463638
39. De Vlas S, Gryseels B, Van Oortmarssen G, Polderman A, Habbema J, A model for variations in single and repeated egg counts in Schistosoma mansoni infections. Parasitology. 1992;104(03):451–60.
40. Katz N, Chaves A, Pellegrino J, A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Tropl São Paulo. 1972;14(6):397–400.
41. Olliaro PL, Vaillant M, Hayes DJ, Montresor A, Chitsulo L, Practical dosing of praziquantel for schistosomiasis in preschool-aged children. Trop Med Int Health. 2013;18(9):1085–9. doi: 10.1111/tmi.12152 23937700
42. Coulibaly JT, N'Gbesso YK, Knopp S, Keiser J, N'Goran EK, Utzinger J, Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Neglect Trop D. 2012;6(12):e1917. doi: 10.1371/journal.pntd.0001917 23236526
43. Garba A, Lamine MS, Barkiré N, Djibo A, Sofo B, Gouvras AN, et al. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop. 2013;128(2):334–44. doi: 10.1016/j.actatropica.2012.08.008 22940014
44. Muhumuza S, Olsen A, Katahoire A, Kiragga AN, Nuwaha F, Effectiveness of a Pre-treatment Snack on the Uptake of Mass Treatment for Schistosomiasis in Uganda: A Cluster Randomized Trial. PLoS Med. 2014;11(5):e1001640. doi: 10.1371/journal.pmed.1001640 24824051
45. Vennervald BJ, Booth M, Butterworth AE, Kariuki HC, Kadzo H, Ireri E, et al. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni. Trans R Soc Trop Med Hyg. 2005;99(2):150–60. 15607341
46. Breslow N, Day N, Statistical Methods in Cancer Research: The Analysis of Case-control Studies. v. 1, Scientific Publication 32. Intl Agency Res Cancer. 1980.
47. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J, Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013;2.
48. Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. 2006.
49. Notterman DA, Nardi M, Saslow JG, Effect of dose formulation on isoniazid absorption in two young children. Pediatrics. 1986;77(6):850–2. 3086830
50. Standing JF, Tuleu C, Paediatric formulations—Getting to the heart of the problem. Intl J Pharm. 2005;300(1):56–66.
51. Kabatereine N, Kemijumbi J, Ouma J, Sturrock R, Butterworth A, Madsen H, et al. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg. 2003;97(5):599–603. 15307437
52. Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A, Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg. 1998;92(1):90–3. 9692165
53. Giboda M, Smith J, Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice. J Trop Med Hyg. 1994;97(2):98–102. 8170010
54. Sabah A, Fletcher C, Webbe G, Doenhoff M, Schistosoma mansoni: Chemotherapy of infections of different ages. Exp Parastol. 1986;61(3):294–303. 3086114
55. Montresor A, Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. Trans R Soc Trop Med Hyg. 2011;105(7):361–3. doi: 10.1016/j.trstmh.2011.04.003 21612808
56. Utzinger J, N'goran EK, N'dri A, Lengeler C, Tanner M, Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health. 2000;5(11):771–8. 11123824
57. Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, et al. Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni. PLoS neglected tropical diseases. 2010;4(3).
58. Woolhouse M, Hagan P, Seeking the ghost of worms past. Nature Med. 1999;5(11).
59. de Moira AP, Jones FM, Wilson S, Tukahebwa E, Fitzsimmons CM, Mwatha JK, et al. Effects of Treatment on IgE Responses against Parasite Allergen-Like Proteins and Immunity to Reinfection in Childhood Schistosome and Hookworm Coinfections. Infect Immun. 2013;81(1):23–32. doi: 10.1128/IAI.00748-12 23071136
60. Webster M, Fallon P, Fulford A, Butterworth A, Ouma J, Kimani G, et al. Effect of praziquantel and oxamniquine treatment on human isotype responses to Schistosoma mansoni: elevated IgE to adult worm. Parasit Immunol. 1997;19(7):333–5. 9278946
61. Butterworth A, Human immunity to schistosomes: some questions. Parasitol Today. 1994;10(10):378–80. 15275540
62. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA, Human IgE, IgG4 and resistance to reinfection with Schistosomahaematobium. 1991. 1898985
63. Mutapi F, Ndhlovu P, Hagan P, Woolhouse M, Changes in specific anti-egg antibody levels following treatment with praziquantel for Schistosoma haematobium infection in children. Parasit Immunol. 1998;20(12):595–600. 9990644
64. Cundill B, Alexander N, Bethony JM, Diemert D, Pullan RL, Brooker S, Rates and intensity of re-infection with human helminths after treatment and the influence of individual, household, and environmental factors in a Brazilian community. Parasitology. 2011;138(11):1406–16. doi: 10.1017/S0031182011001132 21819640
65. Olds G, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Diseases. 1999;179(4):996–1003. 10068597
66. Raso G, N’Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans R Soc Trop Med Hyg. 2004;98(1):18–27. 14702835
67. Polderman A, Gryseels B, Gerold J, Mpamila K, Manshande J, Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg. 1984;78(6):752–4. 6335929
68. Björklund H, Bylund G, Absorption, distribution and excretion of the anthelmintic praziquantel (Droncit) in rainbow trout (Salmo gairdneri R.). Parastol Res. 1987;73(3):240–4.
69. Mennella JA, Beauchamp GK, Optimizing oral medications for children. Clin Ther. 2008;30(11):2120–32. doi: 10.1016/j.clinthera.2008.11.018 19108800
70. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37. doi: 10.1681/ASN.2008030287 19158356
71. Richter J, The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop. 2003;86(2):161–83.
72. Vennervald BJ, Dunne DW, Morbidity in schistosomiasis: an update. Curr Opin Infect Dis. 2004;17(5):439–47. 15353964